1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Li, H. Bowling, J.J. Hamann, M.T. Jung, J.H. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic C3 H7 N O2 89.093 y ALANINE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C5 H7 N O3 129.114 n PYROGLUTAMIC ACID L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking To be Published 0353 Sponge Derived Linear Knottins as a Novel Scaffold for Oral Peptide Drug Administration 10.2210/pdb2lzx/pdb pdb_00002lzx 3905.369 Asteropsin B 1 nat polymer no yes (PCA)GCAFEGESCNVEFYPCCPGLGLTCIPGNPDGTCYYL QGCAFEGESCNVEFYPCCPGLGLTCIPGNPDGTCYYL A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n sample 350938 Asteropus entity_poly pdbx_struct_mod_residue struct_conn database_2 pdbx_database_status repository Initial release Derived calculations Polymer sequence Database references Other 1 0 2013-10-23 2 0 2019-12-25 2 1 2023-06-14 _entity_poly.pdbx_seq_one_letter_code_can _pdbx_struct_mod_residue.parent_comp_id _struct_conn.pdbx_leaving_atom_flag _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_database_status.status_code_nmr_data BMRB Y RCSB 2012-10-11 REL REL REL REL structures with the lowest energy 200 20 2D DQF-COSY 2D 1H-1H TOCSY 2D 1H-1H NOESY 2D 1H-13C HSQC 10 mM 7.0 ambient 298 K simulated annealing 1 lowest energy 10 mM ABU8-2, DMSO-d6 DMSO-d6 Brunger, Adams, Clore, Gros, Nilges and Read structure solution CNS 1.3 Brunger, Adams, Clore, Gros, Nilges and Read refinement CNS 1.3 600 Varian INOVA Varian INOVA 500 Varian INOVA Varian INOVA PCA 1 n 1 PCA 1 A GLY 2 n 2 GLY 2 A CYS 3 n 3 CYS 3 A ALA 4 n 4 ALA 4 A PHE 5 n 5 PHE 5 A GLU 6 n 6 GLU 6 A GLY 7 n 7 GLY 7 A GLU 8 n 8 GLU 8 A SER 9 n 9 SER 9 A CYS 10 n 10 CYS 10 A ASN 11 n 11 ASN 11 A VAL 12 n 12 VAL 12 A GLU 13 n 13 GLU 13 A PHE 14 n 14 PHE 14 A TYR 15 n 15 TYR 15 A PRO 16 n 16 PRO 16 A CYS 17 n 17 CYS 17 A CYS 18 n 18 CYS 18 A PRO 19 n 19 PRO 19 A GLY 20 n 20 GLY 20 A LEU 21 n 21 LEU 21 A GLY 22 n 22 GLY 22 A LEU 23 n 23 LEU 23 A THR 24 n 24 THR 24 A CYS 25 n 25 CYS 25 A ILE 26 n 26 ILE 26 A PRO 27 n 27 PRO 27 A GLY 28 n 28 GLY 28 A ASN 29 n 29 ASN 29 A PRO 30 n 30 PRO 30 A ASP 31 n 31 ASP 31 A GLY 32 n 32 GLY 32 A THR 33 n 33 THR 33 A CYS 34 n 34 CYS 34 A TYR 35 n 35 TYR 35 A TYR 36 n 36 TYR 36 A LEU 37 n 37 LEU 37 A author_defined_assembly 1 monomeric A PCA 1 PYROGLUTAMIC ACID A PCA 1 GLN 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 A N CYS 10 A N CYS 10 A O GLY 32 A O GLY 32 A O TYR 35 A O TYR 35 A N THR 24 A N THR 24 1 A PHE 14 -148.72 -45.02 1 A TYR 15 -115.56 74.20 2 A PHE 14 -148.91 -44.97 2 A TYR 15 -115.61 74.16 3 A PHE 14 -148.80 -45.01 3 A TYR 15 -115.58 74.21 4 A PHE 14 -149.03 -45.20 4 A TYR 15 -115.49 74.16 5 A PHE 14 -148.90 -45.07 5 A TYR 15 -115.57 74.20 6 A PHE 14 -148.84 -45.13 6 A TYR 15 -115.55 74.18 7 A PHE 14 -149.09 -45.01 7 A TYR 15 -115.67 74.13 8 A PHE 14 -148.91 -44.96 8 A TYR 15 -115.45 73.99 9 A PHE 14 -148.95 -45.12 9 A TYR 15 -115.64 74.17 10 A PHE 14 -148.82 -45.02 10 A TYR 15 -115.57 74.27 10 A CYS 17 -69.96 -177.73 11 A PHE 14 -148.98 -45.01 11 A TYR 15 -115.59 74.20 12 A PHE 14 -149.03 -44.75 12 A TYR 15 -115.47 73.92 13 A PHE 14 -148.81 -45.01 13 A TYR 15 -115.42 74.05 14 A PHE 14 -148.94 -45.00 14 A TYR 15 -115.63 74.22 15 A PHE 14 -149.02 -45.05 15 A TYR 15 -115.58 74.10 16 A PHE 14 -148.80 -44.97 16 A TYR 15 -115.44 74.07 17 A PHE 14 -147.54 -44.94 17 A TYR 15 -115.69 74.20 18 A PHE 14 -149.06 -45.13 18 A TYR 15 -115.58 74.15 19 A PHE 14 -148.97 -44.86 19 A TYR 15 -115.38 74.07 20 A PHE 14 -148.78 -45.02 20 A TYR 15 -115.69 74.22 Solution NMR structure of Asteropsin B from a marine sponge Asteropus sp. 1 N N disulf 2.032 A CYS 3 A SG CYS 3 1_555 A CYS 18 A SG CYS 18 1_555 disulf 2.028 A CYS 10 A SG CYS 10 1_555 A CYS 25 A SG CYS 25 1_555 disulf 2.031 A CYS 17 A SG CYS 17 1_555 A CYS 34 A SG CYS 34 1_555 covale 1.336 both A PCA 1 A C PCA 1 1_555 A GLY 2 A N GLY 2 1_555 TOXIN KNOTTIN, SPONGE, TOXIN A ILE 26 A ILE 26 1 A PRO 27 A PRO 27 -0.10 A ASN 29 A ASN 29 1 A PRO 30 A PRO 30 -0.18 A ILE 26 A ILE 26 2 A PRO 27 A PRO 27 -0.02 A ASN 29 A ASN 29 2 A PRO 30 A PRO 30 -0.24 A ILE 26 A ILE 26 3 A PRO 27 A PRO 27 -0.12 A ASN 29 A ASN 29 3 A PRO 30 A PRO 30 -0.18 A ILE 26 A ILE 26 4 A PRO 27 A PRO 27 -0.12 A ASN 29 A ASN 29 4 A PRO 30 A PRO 30 -0.27 A ILE 26 A ILE 26 5 A PRO 27 A PRO 27 -0.12 A ASN 29 A ASN 29 5 A PRO 30 A PRO 30 -0.21 A ILE 26 A ILE 26 6 A PRO 27 A PRO 27 -0.08 A ASN 29 A ASN 29 6 A PRO 30 A PRO 30 -0.20 A ILE 26 A ILE 26 7 A PRO 27 A PRO 27 -0.12 A ASN 29 A ASN 29 7 A PRO 30 A PRO 30 -0.13 A ILE 26 A ILE 26 8 A PRO 27 A PRO 27 -0.15 A ASN 29 A ASN 29 8 A PRO 30 A PRO 30 -0.16 A ILE 26 A ILE 26 9 A PRO 27 A PRO 27 -0.24 A ASN 29 A ASN 29 9 A PRO 30 A PRO 30 -0.17 A ILE 26 A ILE 26 10 A PRO 27 A PRO 27 -0.01 A ASN 29 A ASN 29 10 A PRO 30 A PRO 30 -0.17 A ILE 26 A ILE 26 11 A PRO 27 A PRO 27 -0.11 A ASN 29 A ASN 29 11 A PRO 30 A PRO 30 -0.11 A ILE 26 A ILE 26 12 A PRO 27 A PRO 27 -0.08 A ASN 29 A ASN 29 12 A PRO 30 A PRO 30 -0.21 A ILE 26 A ILE 26 13 A PRO 27 A PRO 27 -0.04 A ASN 29 A ASN 29 13 A PRO 30 A PRO 30 -0.16 A ILE 26 A ILE 26 14 A PRO 27 A PRO 27 -0.10 A ASN 29 A ASN 29 14 A PRO 30 A PRO 30 -0.13 A ILE 26 A ILE 26 15 A PRO 27 A PRO 27 -0.22 A ASN 29 A ASN 29 15 A PRO 30 A PRO 30 -0.20 A ILE 26 A ILE 26 16 A PRO 27 A PRO 27 -0.11 A ASN 29 A ASN 29 16 A PRO 30 A PRO 30 -0.11 A ILE 26 A ILE 26 17 A PRO 27 A PRO 27 -0.19 A ASN 29 A ASN 29 17 A PRO 30 A PRO 30 -0.02 A ILE 26 A ILE 26 18 A PRO 27 A PRO 27 -0.17 A ASN 29 A ASN 29 18 A PRO 30 A PRO 30 -0.12 A ILE 26 A ILE 26 19 A PRO 27 A PRO 27 -0.20 A ASN 29 A ASN 29 19 A PRO 30 A PRO 30 -0.18 A ILE 26 A ILE 26 20 A PRO 27 A PRO 27 -0.01 A ASN 29 A ASN 29 20 A PRO 30 A PRO 30 -0.15 2LZX PDB 1 2LZX 1 37 2LZX 1 37 2LZX A 1 1 37 3 anti-parallel anti-parallel A SER 9 A SER 9 A ASN 11 A ASN 11 A ASP 31 A ASP 31 A TYR 36 A TYR 36 A LEU 23 A LEU 23 A ILE 26 A ILE 26